Holen Sie sich die Stockscreener-App
0.881
2.35%
0.0202
Handel nachbörslich:
.96
0.079
+8.97%
Estrella Immunopharma Inc Aktie (ESLA) Neueste Nachrichten
Estrella Immunopharma Expands STARLIGHT-1 Trial with New Texas Clinical Site - MSN
Estrella Immunopharma opens new trial site for cancer therapy By Investing.com - Investing.com South Africa
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II Starlight-1 Trial in B-Cell Non-Hodgkin's Lymphoma - MarketScreener
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - BioSpace
Estrella Immunopharma (ESLA) Expands Clinical Trial with New Sit - GuruFocus
Estrella Immunopharma opens new trial site for cancer therapy - Investing.com Australia
Estrella Immunopharma Expands STARLIGHT-1 Clinical Trial - TipRanks
Estrella Immunopharma Announces Activation Of Additional Site For Phase I/Ii Starlight-1 Trial In B-Cell Non-Hodgkin'S Lymphoma - marketscreener.com
Estrella Immunopharma secures $3.35M in financing to advance clinical triall; shares up - MSN
Analyst Maintains Buy Rating on Estrella Immunopharma (ESLA) | E - GuruFocus
Estrella Immunopharma secures $3.35 million in PIPE financing By Investing.com - Investing.com South Africa
Analyst Maintains Buy Rating on Estrella Immunopharma (ESLA) | ESLA Stock News - GuruFocus
Estrella Immunopharma (ESLA) Secures $3.35M Through Private Equi - GuruFocus
Estrella Immunopharma secures $3.35 million in PIPE financing - Investing.com Australia
Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing - Business Wire
Estrella Immunopharma’s (ESLA) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial - Yahoo
ESLA Stock Rating and Price Target Maintained by D. Boral Capita - GuruFocus
Estrella Immunopharma, Inc. Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas - marketscreener.com
Estrella Immunopharma Advances STARLIGHT-1 Clinical Trial - TipRanks
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas - BioSpace
ESLA Stock Rating and Price Target Maintained by D. Boral Capital | ESLA Stock News - GuruFocus
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas - marketscreener.com
Estrella Immunopharma (ESLA) Advances in Phase I/II STARLIGHT-1 Trial | ESLA Stock News - GuruFocus
Geode Capital Management LLC Acquires 16,862 Shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) - Defense World
ESLA Stock: A Voyage Through Estrella Immunopharma Inc’s Finances - investchronicle.com
A stock that deserves closer examination: Estrella Immunopharma Inc (ESLA) - uspostnews.com
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners - BioSpace
Estrella Immunopharma completes first dose cohort in STARLIGHT trial - Yahoo Finance
Sector Update: Health Care -February 21, 2025 at 03:42 pm EST - Marketscreener.com
Estrella Immunopharma Completes First Dose Group in Non-Hodgkin Lymphoma Study - Marketscreener.com
Estrella Immunopharma Completes First Dose Cohort In Starlight-1 Trial And Receives Approval To Initiate Higher Dose Cohort - Marketscreener.com
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort - The Bakersfield Californian
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital - 01net
Estrella Immunopharma (NASDAQ:ESLA) Now Covered by Analysts at D. Boral Capital - Defense World
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Estrella Immunopharma regains Nasdaq compliance - Investing.com
Estrella Immunopharma faces Nasdaq delisting over equity shortfall - Investing.com
Spotlight On US Penny Stocks: Estrella Immunopharma And Two Others To Consider - Simply Wall St
Eureka Therapeutics Tackling Advanced Hepatocellular Carcinoma With T-Cell Therapy ECT204 in Phase 1/2 ARYA-3 Clinical Trial - CGTLive™
Tesla stock hits 52-week low at $0.75 amid market challenges - Investing.com
Around the Helix: Cell and Gene Therapy Company Updates – October 9, 2024 - CGTLive™
First Patient Dosed Achieves Complete Response in Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas - CGTLive®
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS - Business Wire
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member - Business Wire
Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas Doses First Patient - CGTLive®
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):